Bortezomib

Bortezomib is an anti-cancer drug used for the treatment of multiple myeloma cancer and mantle cell lymphoma. Multiple myeloma is a cancer of the blood plasma cells that provide and produce antibodies.

Merek dagang bortezomid: Bormib, Bortecade 1, Bortecade 3,5, Bortero, Fonkozomib, Teoxib, Tezobell, Velcade

At this time, data has been obtained that supports an improvement in life expectancy from several newly introduced immunomodulatory drugs, namely thalidomide, lenalidomide and proteasome enzyme inhibitors, namely bortezomib.
in combination with old drugs. Each of these drugs has multiple mechanisms of action, targeting both intracellular access and the environment surrounding the tumor. Formerly known as PS-341 and is the first proteasome inhibitor in research. This drug has been approved by the FDA for the treatment of advanced multiple myeloma since May 2003.
Bortezomib is a proteasome inhibitor anti-neoplastic agent (proteasome inhibitor) which functions to stop the cycle of protein intake to restrain and kill cancer cells. Bortezomib is used to treat multiple myeloma, which is a cancer that attacks the plasma cells in the bone marrow. In addition, this drug is also used to treat Mantle cell lymphoma, cancer that develops in an area within the lymph nodes, called the mantle zone.
The drug bortezomib belongs to the class of antineoplastic drugs. Bortezomib has the following benefits, a proteasome inhibitor or proteasome inhibitor which functions to stop protein intake in the growth cycle of cancer cells. Stop and separate cancer cells that aim to kill the development of cancer cells. Prevent and kill cancer cells before they spread. The way it works is by blocking certain proteins to help slow the growth and spread of cancer. Bortezomib is given by injection into a vein or under the skin. Use of this drug can cause dehydration or lack of fluids. So, drink plenty of fluids while on this medication. Always follow the doctor's advice or read the instructions on the bortezomib packaging before use.
Bortezomib is given directly by a doctor or medical personnel under the supervision of a doctor. Drug use generally has certain side effects and is individual. If there are excessive side effects, they must be treated by medical personnel immediately. Inform and consult with your doctor about your previous medical history, if any. Store at the recommended temperature on the packaging.
Drug interactions may occur when using or taking several drugs simultaneously. Be sure to always consult a doctor before using it. If necessary, the doctor may reduce the dose or replace the drug with another alternative drug.

References:

- Bortezomib Retreatment Is Effective in Relapsed Multiple Myeloma Patients - Real-life Clinical Practice Data.
- Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later.
- Bortezomib.
- Bortezomib (Velcade).
- Bortezomib 2.5mg/ml Solution for Injection (3.5mg Total Content).
- Velcade (Bortezomib) Information.
- Drugs and Supplements. Bortezomib (Intravenous Route, Subcutaneous Route).
- Bortezomib (Rx).
- Bortezomib Solution, Reconstitued (Recon Soln).